Nasdaq

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, ...

ConcertAI and Foundation Medicine Integrate Genomic and Clinical Data to Transform Translational Research and Efficient Drug Development

ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, and Foundation Medicine, a global, ...
FiercePharma

Foundation Medicine and Dana-Farber Cancer Institute Identify Novel Genomic Alterations in Lung and Colorectal Cancer

Findings Published in Nature Medicine Highlight Clinical Application of Next-Generation Sequencing to Suggest Targeted Therapeutic Options for Patients CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation ...
Business Wire

Foundation Medicine Awarded Contract by the U.S. Department of Veterans Affairs to Provide Tumor Molecular Profiling to Veterans with Cancer

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc. today announced it was awarded its second consecutive, five-year contract by the U.S. Department of Veterans Affairs (VA) to provide tumor molecular ...
Nasdaq

Foundation Medicine Partners with Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the ...

BOSTON--(BUSINESS WIRE)-- Foundation Medicine, Inc. today announced a collaboration with Syndax Pharmaceuticals (Nasdaq: SNDX) to develop a companion diagnostic for the identification of acute myeloid ...
Becker's Hospital Review

Cancer Treatment Centers of America, Foundation Medicine team up for precision medicine awareness campaign

Boca Raton, Fla.-based Cancer Treatment Centers of America and Foundation Medicine are collaborating on an educational campaign to raise awareness regarding the potential of precision medicine.
The American Journal of Managed Care

FDA Approves FoundationOne Liquid CDx as a Diagnostic Tool for BRCA-Mutated mCRPC

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...